Immune Profiling April 12

Dr Joseph Breen
09:00

Chair’s opening remarks

Dr Joseph Breen, Immunoregulation Section Chief, Basic Immunology Branch, Division of Allergy, Immunology and Transplantation, NIAID, NIH, National Institute of Allergy and Infectious Diseases
Dr Roy Baynes
09:10

PD-1 Antibodies have the potential to be a broad spectrum antineoplastic treatment both as monotherapy and in combination therapies  

  • PD-1 antibodies are checkpoint inhibitors for the treatment of cancer and act by targeted activation of the immune system
  • Initial activity screening was based upon big data analyses of PDL-1 status and mutational burden of various cancers
  • PD-1 antibody therapy appears to be a broad spectrum anticancer monotherapy and has the potential to be foundational in combination therapy
  • Toxicity profiles of checkpoint blockade and combination checkpoint blockade inform treatment options
  • Precision medicine appears to be key in certain tumour types
Dr Daniel Zimmerman
09:40

Addressing the unmet need for therapeutic vaccines for autoimmune conditions with emphasis on arthritis

 
  • Exploring the current landscape for vaccine therapeutics for autoimmune conditions
  • Sharing updates, mode of mechanisms, and progress regarding development of a vaccine for Rheumatoid arthritis
Dr Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology, CEL-SCI Corporation
Mr Bruno Gomes
10:10

Characterization of a novel personalized cancer immunotherapy: A best-in-class adenosine A2A receptor antagonist optimized for high potency in adenosine-rich tumor microenvironment

  • Targeting a new immune-checkpoint in cancer
  • Characterization of the immune mechanism of action a novel immune checkpoint blocker
  • Translational strategy to improve the antitumor efficacy in patients
10:40

Networking coffee break

Mr Lei Zheng
11:30

Strategies for effective clinical trial design for combinational immunotherapies

Dr Rakesh Dixit
12:00

Combinational immunotherapy in oncology: Challenges and opportunities

  • Effective immunomodulation and highlighting how drugs of different modalities (e.g., immune checkpoint modulators, cancer vaccines, oncolytic viruses etc.) can be effectively combined to overcome tumor immunosuppression
  • Translational science behind the combinations to attain the best antitumor efficacy
  • Discussing the efficacy and safety of therapeutic combinations
  • Current opportunities, challenges and the potential for unforeseen side effects
  • Thoughts for the future in combination
last published: 21/Mar/17 11:05 GMT

 

>> View the full World Vaccine Congress Washington 2017 Agenda including the 7 co-located event streams